Yuhchyau Chen, MD
Radiation Oncology · Rochester, NYNPI 1730119603
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,655 of the $2,044 with a category attached, or 81.0%. Astrazeneca UK Limited accounts for 86.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $1,836 and has fallen 94.7% since, to $97 in 2024.
Across 13 payments — averaging $157.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$2K
- Siemens Medical Solutions USA, Inc.$111
- AstraZeneca$73
- Boston Scientific$53
- Progenics Pharmaceuticals, Inc.$44
Across 11 payments — averaging $49,225 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$501K
- Helsinn Healthcare SA$36K
- Merck$5K
What the payments were for
- Travel & lodging$1,65581%
- Food & beverage$38819%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 8 | $1,762 |
| Siemens Medical Solutions USA, Inc. | 1 | $111 |
| AstraZeneca | 2 | $73 |
| Boston Scientific | 1 | $53 |
| Progenics Pharmaceuticals, Inc. | 1 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$1,530
- Varian Ethos Treatment Planning$111
How this compares
$2,044 in reported general payments places this provider in the 75th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluconazole | 16 | $385 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Rochester
- Michael MilanoRochester$6K
- Chung ChungSyracuse$3.1M
- Michael ZelefskyNew York$946K
- Jeffrey BogartSyracuse$772K
- Steven FinkelsteinSyracuse$578K
- Shawn ZimbergPlainview$411K
- Edward ObedianOyster Bay$391K
- Nancy LeeNew York$233K
- Dheerendra PrasadBuffalo$178K
- Robert SamsteinNew York$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.